Právní předpis byl sestaven k datu 01.01.2025.
Zobrazené znění právního předpisu je účinné od 01.01.2025.
419
XXXXXXXX XXXXX
xx xxx 11. xxxxxxxx 2024,
kterým xx xxxx xxxxxxxx xxxxx x. 463/2013 Xx., x xxxxxxxxx xxxxxxxxxx látek, xx xxxxx xxxxxxxxxx xxxxxxxx
&xxxx;
Xxxxx xxxxxxxx xxxxx §44c xxxx. 1 a 2 xxxxxx č. 167/1998 Sb., x xxxxxxxxxx xxxxxxx x x změně xxxxxxxxx xxxxxxx zákonů, ve xxxxx xxxxxx č. 273/2013 Xx. a xxxxxx x. 366/2021 Xx.:
Xx. X
Xxxxxxxx xxxxx x. 463/2013 Xx., x xxxxxxxxx xxxxxxxxxx xxxxx, ve xxxxx xxxxxxxx vlády x. 243/2015 Xx., nařízení xxxxx x. 46/2017 Xx., xxxxxxxx xxxxx x. 30/2018 Xx., xxxxxxxx vlády x. 242/2018 Xx., nařízení xxxxx x. 184/2021 Xx., nařízení vlády x. 159/2022 Sb., xxxxxxxx xxxxx x. 228/2023 Xx., xxxxxxxx xxxxx č. 52/2024 Xx. x xxxxxxxx xxxxx x. 176/2024 Xx., xx xxxx xxxxx:
1. X tabulce xxxxxxx x. 1 xx xxx xxxxx, xx kterém xx xx xxxxxxx x xxxxxx „Xxxxxxxxxxx nechráněný xxxxx (XXX) v xxxxxx jazyce“ xxxxxxx xxxxx „Xxxxxxxx“, xxxxxx xxxx řádek, xx xxxxxx je xx xxxxxxx s xxxxxx „Xxxxxxxxxxx nechráněný název (XXX) v českém xxxxxx“ xxxxxxx xxxxx „Xxxxxxxxxxxx“, xx xxxxxxx x názvem „Chemický xxxxx podle IUPAC“ xx xxxxxxx slovo „xxxxxx 4-(X-(2-xxxxxxxxxxxxx)xxxxxx)-1-(2-xxxxxxx-2-xxxxxxx)xxxxxxxxx-4-xxxxxxxxxx“ x xx xxxxxxx x xxxxxx „Xxxxxxxx“ xxxx xxxxxxx xxxxx „X-3080, Xxxxxxx“.
2. Příloha č. 3 xxx:
„Xxxxxxx x. 3
Xxxxxx x. 3 xxxxxxxx xxxxx
|
Xxxxxxxxxxx xxxxxxxxxx xxxxx (INN) v českém xxxxxx / xxxxxx xxxxx |
Xxxxx mezinárodní nechráněný xxxxx nebo xxxxx xxxxxx název |
Chemický název xxxxx XXXXX |
Xxxxxxxx |
|
Xxxxxxxxxxxxxxxxxxxx |
xxxxxxxxxxxxxxxxxxxx |
X-xxxxx-X-(1-xxxxxx-xxxxxxxxx-4-xx)-xxxxxxxx |
XXX 73750 |
|
Xxxxxxxxxxxxxx |
X-xxxxx-X-[1-(2-xxxxxxxxxx)-4-xxxxxxxxxxx]xxxxxxxx |
||
|
Xxxxxxxxxxxxxxxx |
Xxxxxxxxxxxxx |
X-xxxxx-X-[1-(2-xxxxxxxxxx)xxxxxxxxx-4-xx]xxxx-2-xxxxxx |
|
|
XX-7921 |
3,4-xxxxxxx-X-{[1-(xxxxxxxxxxxxx)xxxxxxxxxx]xxxxxx}xxxxxxxx |
||
|
XX-237 |
xxxxxxxxxx; 1-X-xxxxxxx-4- cinnamylpiperazine; |
1-[4-(3-fenylprop-2-en-1-yl)piperazin-1-yl]butan-1-on |
|
|
AP-238 |
1-[2,6-dimethyl-4-(3-fenylprop-2-enyl)piperazin-1-yl]propan-1-on |
||
|
Benzodioxolfentanyl |
BZD-F; xxxxxxxxxxxx-X |
X-xxxxx-X-[1-(2-xxxxxxxxxx)xxxxxxxxx-4-xx-1-2X-1,3-xxxxxxxxxxx-5-xxxxxxxxxx |
|
|
Xxxxxxxxxxxxxxxxxxxxx |
X-xxxxx-X-(1-xxxxxx-xxxxxxxxx-4-xx)xxxxxxxx |
||
|
Xxxxxxxxxxxxxxx |
xxxxxxxxxxxxx |
X-xxxxx-X-[1-(2-xxxxxxxxxx)xxxxxxxxx-4-xx]xxxxxxxx |
|
|
Xxxxxxxxxxxxxx |
Xxxxxx-X; X4129 |
X-xxxxx-X-[1 -(xxxxxxxxxxx)xxxxxxxxx-4-xx]xxxxxxxxxx |
|
|
Xxxxxxxxxxxxxxxxxxxxx |
Xxxxxx XxX |
X-(1-xxxxxxxxxxxxxxx-4-xx)-X-xxxxxxxxxx-2-xxxxxxxxxx |
|
|
Xxxxxxxxxx |
X 4793x; U 47931E |
4-brom-N-(2-(dimethylamino) xxxxxxxxxx) benzamid |
|
|
Brorfin |
Brorphine |
3-{1-[1-(4-bromfenyl)ethyl]piperidin-4-yl}-1H-benzimidazol-2-on |
|
|
Butonitazen |
2-[(4-butoxyfenyl)methyl]-N,N-diethyl-5-nitro-lA-benzimidazol-1-ethanamin |
||
|
4-Chlorisobutyrfentanyl |
4-Cl-iBF |
N-(4-chlorfenyl)-2-methyl-N-[1-(2-fenylethyl)-4-piperidinyl]propanamid |
|
|
Cyklopentylfentanyl |
cyclopentyl-F; XX-X |
X-xxxxx-X-[1-(2-xxxxxxxxxx)xxxxxxxxx-4-xx]xxxxxxxxxxxxxxxxxxxxx |
|
|
Xxxxxxxxxxxxxxxxxxx |
X-xxxxx-X-[1-(2-xxxxxxxxxx)xxxxxxxxx-4-xx]xxxxxxxxxxxxxxxxxxxxx |
||
|
Xxxxxxxxxxxxxxxx |
X530 |
4-(4-xxxxxxxxxx)-2,2-xxxxxxx-1-(1-xxxxxxxxxxxx)-1-xxxxxxx |
|
|
Xxxxxxxxxx |
4,5α-xxxxx-17-xxxxxxxxxxxxxx-3-xx |
||
|
Xxxxxxxxxxxx-2-xxxxx xxxxxxxx |
X-(2-xxxxxxxxxx)-1-(2-xxxxxxxxxx)xxxxxxxxx-4-xxxx |
||
|
Xxxxxxxxxxxx-4-xxxxx xxxxxxxx |
X-(4-xxxxxxxxxx)-1-(2-xxxxxxxxxx)xxxxxxxxx-4-xxxx |
||
|
Xxxxxxxx |
4,4-xxxxxxx-6-(xxxxxxxxxx-1-xx)xxxxxx-3-xx |
||
|
Xxxxxx |
xxxxxxxxxxxxxx |
2-[2-[(4-xxxxxxxxxxx)xxxxxx]xxxxxxxxxxxx-1-xx]-X,X-xxxxxxxxxxxxxxxx |
|
|
Xxxxxxxxxxxxxxxxx |
2-{2-[(2,3-xxxxxxx-1-xxxxxxxxxx-5-xx)xxxxxx]-5-xxxxx-1X-xxxxxxxxxxxx-1-xx}-X,X- xxxxxxxxxxxx-1-xxxx |
||
|
Xxxxxxxxxx |
5-xxxxxx xxxxxxxxxxxxx; 5-xxxxxx xxxxxxxxxxxxxxxxxx |
2-[(4-xxxxxxxxxxx)xxxxxx]-X,X-xxxxxxx-5-xxxxxx-1X-xxxxxxxxxxxx-1-xxxxxxxxx |
|
|
Xxxxxxxxxxxxxx |
X-xxxxxxxxxxxxxxxxxxxxx |
2-(4-xxxxxxxxxxxx)-5-xxxxx-1-(2-(xxxxxxxxx-1-xx)xxxxx)-1X-xxxxx[x]xxxxxxxx |
|
|
Xxxxxxxxxxxx |
2-[(4-xxxxxxxxxxx)xxxxxx]-5-xxxxx-1-(2-xxxxxxxxxx-1-xxxxxxx)-1X-xxxxxxxxxxxxx |
||
|
Xxxxxxx |
(5X,6X,7X,14X)-4,5-xxxxx-7-[(2X)-2-xxxxxxxxxxxxx-2-xx]-6-xxxxxxx-17-xxxxxx-6,14-xxxxxxxxxxxxxx-3-xx |
||
|
Xxxxxxxx butanamid xxxxxx |
xxxxxxxxxxxxx |
X-xxxxx-X-[1-(2-xxxxxxxxxx)-4-xxxxxxxxxxx]-xxxxxxxxx |
|
|
3 -Fenylropanoylfentanyl |
β'-fenylfentanyl |
N-fenyl-N-[1-(2-fenylethyl)piperidin-4-y]-3-fenylpropanamid |
hydrocinnamoylfentanyl |
|
Flunitazen |
N,N-diethyl-2-{2-[(4-fluorfenyl)methyl]-5-nitro-1N-benzimidazol-1-yl}ethanamin |
||
|
2’-Fluor-2-fluor-3-methylfentanyl |
N-(1-(2-fluorfenethyl)-3-methylpiperidin-4-yl)-N-(2-fluorfenyl)propionamid |
||
|
4-Fluor-butyrfentanyl |
4F-BF |
N-(4-fluorfenyl)-N-[(1-(2-fenylethyl)-4-piperidinyl)]butanamid |
|
|
4-Fluor-cyklopropylbenzylfentanyl |
para-fluorcyklopropylbenzyl- xxxxxxxx |
X-(4-xxxxxxxxxx)-X-(1-xxxxxxxxxxxxxxx-4-xx)-xxxxxxxxxxxxxxxxxxxxx |
|
|
2-Xxxxxxxxxxxxx |
Xxxxxxxxxxxxxxxxx |
X-(2-xxxxxxxxxx)-X-[1-(2-xxxxxxxxxx)-4-xxxxxxxxxxx]xxxxxxxxxx |
2-XX, x-XX |
|
3-Xxxxxxxxxxxxx |
Xxxxxxxxxxxxxxxxx |
X-(3-xxxxxxxxxx)-X-[1-(2-xxxxxxxxxx)-4-xxxxxxxxxxx]xxxxxxxxxx |
3-XX, x-XX |
|
4-Xxxxxxxxxxxxxxxxxxxx |
xxxx-xxxxxxxxxxxxxxxxxxxx; 4X-xxxxxxxxxxxxxxx |
X-(4-xxxxxxxxxx)-X-(1-xxxxxxxxxxxxxxxxx-4-xx)xxxxx-2-xxxxxxxxxx |
|
|
4-Xxxxxxxxxxxxxxxxxxxxx |
4X-1XX |
X-(4-xxxxxxxxxx)-2-xxxxxx-X-[1-(2-xxxxxxxxxx)-4-xxxxxxxxxxx]xxxxxxxxxx |
|
|
3-XxxxxxxxxxxxxxxxxXxxxxxxxx |
xxxxx-xxxxxxxxxxxxxxxxxx- xxxxxxxx |
X-(3-xxxxxxxxxx)-2-xxxxxxx-X-[1-(2-xxxxxxxxxx)xxxxxxxxx-4-xx]xxxxxxxx |
|
|
2X-xxxxxxx |
2-[xx(xxxxx-2-xx)xxxxx]-1-[1-(2-xxxxxxxxxxx)-1X-xxxxxx-2-xx]xxxxx-1-xx |
||
|
Xxxxxxx UF-17 |
N-[2-(dimethylamino)cyklohexyl]-N-fenyl-furan-2-karboxamid |
||
|
Furanylfentanyl |
FU-F; 2-xxxxxxxxxxxxxxxx |
X-xxxxx-X-[1-(2-xxxxxxxxxx)xxxxxxxxx-4-xx]-xxxxx-2-xxxxxxxxxx |
|
|
(xxx)Xxxxxxx-X-xxxxxxxx X-xxxxxx xxxxxx |
X-(1-xxxxxxxxxxxxxxx-4-xx)-X-(4-xxxxxxxxxx)xxxxxxxxx |
||
|
Xxxxxx |
(5X,6X)-4,5-xxxxx-17-xxxxxxxxxxxx-7-xx-3,6-xxxx-xxxxxxxx |
||
|
4-xxxxxxxxxxxxxxxxxxxx |
4-XX-XX; p-hydroxybutyryl xxxxxxxx |
X-(4-xxxxxxxxxxxx)-X-[1-(2-xxxxxxxxxx)xxxxxxxxx-4-xx]-xxxxxxxxx |
|
|
Xxxxxxxxxxxxxxxx |
2-xxxxxx-X-xxxxx-X-[1-(2-xxxxxxxxxx)xxxxxxxxx-4-xx]xxxxxxxxxx |
||
|
Xxxxxxxxx-X-47700 |
3,4-xxxxxxxX-[2-(xxxxxxxxxxxxx)xxxxxxxxxx]-X-(xxxxxx-2-xx)xxxxxxxx |
||
|
Xxxxxxxxxxxx |
X,X-xxxxxxx-2-[[4-(1-xxxxxxxxxxxx)xxxxx]xxxxxx]-5-xxxxx-1X-xxxxxxxxxxxx-1-xxxxx xxxx |
||
|
Xxxxxxxx-xxxxxxxx |
(4-xxxxxxxxx)-(1-(xxxxxxxxxxxxx)-4-xxxxxxx-4-xxxxxxxxxxxxxxxxxx)xxxxxxxx |
||
|
Xxxxxxxxxxx |
1-[4-(3-xxxxxxx xxxxx)-1 -xxxxxxxxxxxxxxx-4-xx]xxxxxx-1-xx |
||
|
Xxxxxx |
X xxxxxxxx xxxxxx xxx xxxxxxx xxxxxxx xxxxxxx x xxxxxxx x.&xxxx;1 |
||
|
Xxxxxxxxxxxxxxxx |
(2X)-X-xxxxx-X-[1-(2-xxxxxxxxxx)xxxxxxxxx-4-xx]-2-xxxxxxxxx |
||
|
Xxxxxxxxxxxxxxxxxxxxx |
Xxxxxxx-XxX |
2-xxxxxxx-X-xxxxx-X-[1-(2-xxxxxxxxxx)xxxxxxxxx-4-xx]xxxxxxxx |
|
|
4-Xxxxxxxxxxxxxxxxxxxx |
4-XxX-XX |
X-(4-xxxxxxxxxxxx)-X-[1-(2-xxxxxxxxxx)xxxxxxxxx-4-xx]xxxxxxxxx |
|
|
2-Xxxxxxxxxxxxxxxxxxxx |
x-xxxxxxxxxxxxxxxxxxxx |
X-(2-xxxxxxxxxxx)-X-[1-(2-xxxxxxxxxx)-xxxxxxxxx-4-xx]-xxxxxxxx |
|
|
2-Xxxxxx-XX-237 |
2-xxxxxx-xxxxxxxxxx |
1-[2-xxxxxx-4-(3-xxxxxxxxx-2-xx-1-xx)xxxxxxxxx-1-xx]xxxxx-1-xx |
|
|
3,4-Xxxxxxxxxxxxx-X-47700 |
3,4-XXX-X-47700; 3,4-XXX-47700; XXX-47; XXX-47700 |
X-(2-(xxxxxxxxxxxxx)xxxxxxxxxx)-X-xxxxxxxxxxx[x][1,3]xxxxxx-5-xxxxxxxxxx |
|
|
α-Xxxxxxxxxxxxxx xxxxxxxxx xxxxxx |
XX; B-F |
2-methyl-N-fenyl-N-[1-(1-fenylpropan-2-yl)piperidin-4-yl]propanamid |
|
|
3 -MethyIkrotonyIfentanyl |
β'-methyIkrotonyIfentanyl |
N-fenyl-A-[1-(2-fenylethyl)-piperidin-4-yl]-3-methylbut-2-enamid |
|
|
Metodesnitazen |
N,N-diethyl-2-[2-[(4-methoxyfenyl)methyl]benzimidazol-1-yl]ethanamin |
||
|
Metonitazen |
N,N-diethyl-2-[2-[(4-methoxyfenyl)methyl]-5-nitrobenzimidazol-1-yl]ethanamin |
||
|
Metonitazepin |
2-(4-methoxybenzyl)-5-nitro-1-(2-(pyrrolidin-1-yl)ethyl)-1H-benzo[d]imidazol |
||
|
MT-45 |
1-cyklohexyl-4-(1,2-difenylethyl)piperazin |
||
|
N-desethyletonitazen |
2-[2-[(4-ethoxyfenyl)methyl]-5-nitro-benzimidazol-1-yl]-N-ethyl-ethanamin |
||
|
N-desethylisotonitazen |
N-ethyl-2-[2-[(4-isopropoxyfenyl)methyl]-5-nitro-benzimidazol-1-yl]ethanamin |
||
|
N-methyl X-47931X |
X-xxxxxxxxxxxxxxxx |
4-xxxx-X-(2-(xxxxxxxxxxxxx)xxxxxxxxxx)-X-xxxxxxxxxxxxxx |
|
|
Xxxxxxxxxx |
xxxxx 2-methylamino-1-fenylcyklohex-3-en-1-karboxylát |
||
|
O-AMKD; acetoxymethylketobemidon |
3-(4-acetyl-1-methylpiperidin-4-yl)fenyl acetát |
||
|
OCfentanyl |
A-3217 |
N-(2-fluorfenyl)-2-methoxy-N-[1-(2-fenylethyl)piperidin-4-yl]acetamid |
|
|
Piperidylthiambuten |
piperidinohton, XXX, 127X49 |
1-(4,4-xx(xxxxxxx-2-xx)xxx-3-xx-2-xx)xxxxxxxxx |
|
|
Xxxxxxxxxxxx |
X,X-xxxxxxx-5-xxxxx-2-[(4-xxxxxxxxxxxx)xxxxxx]-1-X-xxxxxxxxxxxx-1-xxxxxxxxx |
||
|
Xxxxxxxxxxxxxx |
5-xxxxx-2-[(4-xxxxxxxxxxxxx)xxxxxx]-1-(2-xxxxxxxxxx-1-xxxxxxx)xxxxxxxxxxxxx |
||
|
Xxxxxxxxxx x&xxxx;xxxxxx |
|||
|
Xxxxxxxxxxxxxxxxxxxxxxx |
XXX-X |
X-(1-xxxxxxxxxxxxxxxxxxx-4-xx)-X-xxxxxxxxxxxxxxxxxxxx-2-xxxxxxxxxx |
|
|
Xxxxxxxxxxxxxxxxxxxxxxxxxxxxxx |
XXXX-xxxxxxxx; XXXX-X |
X-xxxxx-X-[1-(2-xxxxxxxxxx)xxxxxxxxx-4-xx]-2,2,3,3-xxxxxxxxxxxxxxxxxxxxxx-1- karboxamid |
|
|
Thiofenfentanyl |
2-thiofuranyl xxxxxxxx |
X-(1-xxxxxxxxxxxxxxxxx-4-xx)-X-xxxxxxxxxxxx-2-xxxxxxxxxx |
|
|
4-(Xxxxxxxxxxxxxx) X-47700 |
X-(2-(xxxxxxxxxxxxx)xxxxxxxxxx)-X-xxxxxx-4-(xxxxxxxxxxxxxx)xxxxxxxx |
||
|
X-47700 |
3,4-xxxxxxx-X-[2-(xxxxxxxxxxxxx)xxxxxxxxxx]-X-xxxxxxxxxxxxxx |
||
|
X-48800 |
2-(2,4-xxxxxxxxxxxx)-X-(2-(xxxxxxxxxxxxx)xxxxxxxxxx)-X-xxxxxxxxxxxxxx |
||
|
X-49900 |
3,4-xxxxxxx-X-[2-(xxxxxxxxxxxx)xxxxxxxxxx]-X-xxxxxxxxxxxxxx |
||
|
X-50488 |
3,4-xxxxxxx-X-xxxxxx-X-[2-(1-xxxxxxxxxxxx)xxxxxxxxxx] benzenacetamid |
||
|
U-51754 |
2-(3,4-dichlorfenyl)-N-[2-(dimethylamino)cyklohexyl]-N-methylacetamid |
||
|
ValeryIfentanyl |
TCE, XX |
X-xxxxx-X-[1-(2-xxxxxxxxxx)-4-xxxxxxxxx]xxxxxxxxxx; xxxxxxxx xxxxxxxxxx xxxxxx |
Xxxxxx xxxx omamných látek xxxxxxxxx x xxxx xxxxxxx xx xxxxx xxxxxxxxx, kdy xxxx xxxx xxxxx xxxxxxxxx“.
3. X tabulce xxxxxxx x. 6 xx xxx xxxxx, ve xxxxxx je xx xxxxxxx x xxxxxx „Xxxxxxxxxxx xxxxxxxxxx xxxxx (XXX) v českém xxxxxx“ xxxxxxx xxxxx „Xxxxxxxxxxxxx“, xxxxxx xxxx xxxxx, ve kterém xx xx xxxxxxx x xxxxxx „Xxxxxxxxxxx xxxxxxxxxx název (XXX) x xxxxxx xxxxxx“ xxxxxxx xxxxx „Gamabutyrolakton“, xx xxxxxxx x xxxxxx „Další xxxxxxxxxxx xxxxxxxxxx xxxxx xxxx xxxxx obecný xxxxx“ xx uveden text „XXX“, xx xxxxxxx x názvem „Chemický xxxxx xxxxx IUPAC“ xx xxxxxxx xxxxx „xxxxxx-2-xx“ x xx xxxxxxx s xxxxxx „Xxxxxxxx“ je uvedeno xxxxx „gamma-butyrolactone“.
Xx. II
Technický předpis
Toto xxxxxxxx bylo xxxxxxxx x souladu se xxxxxxxx Xxxxxxxxxx xxxxxxxxxx x Rady (EU) 2015/1535 xx xxx 9. září 2015 x xxxxxxx xxx xxxxxxxxxxx xxxxxxxxx v xxxxxxx xxxxxxxxxxx předpisů x xxxxxxxx pro xxxxxx informační xxxxxxxxxxx.
Xx. XXX
Xxxxxxxx
Xxxx xxxxxxxx xxxxxx xxxxxxxxx xxxx 1. xxxxx 2025, x xxxxxxxx ustanovení čl. I bodu 3, xxxxx xxxxxx účinnosti xxxx 1. xxxxx 2025.
&xxxx;
Xxxxxxxx xxxxx:
xxxx. XxXx. Xxxxx, Xx.X., LL.M., x. r.
Místopředseda xxxxx x xxxxxxx xxxxxxxxxxxxx:
xxxx. XXXx. Xxxxx, XXx., XXX, EBIR, v. x.
Xxxxxxxxx
Xxxxxx xxxxxxx x. 419/2024 Sb. xxxxx xxxxxxxxx dnem 1.1.2025, x xxxxxxxx xxxxxxxxxx čl. I xxxx 3, xxxxx xxxxxx účinnosti 1.4.2025.
Xxxxx xxxxxxxxxxxx xxxxxxxx xxxxx xxxxxx xxxxxxxx xxxxxxxx v xxxxxxxx xxxx xxxxxxxxxxxxx, pokud xx xxxx netýká xxxxxxxxx změna shora xxxxxxxxx xxxxxxxx xxxxxxxx.